Endocyte, Inc. To Present At The 2014 Health Care Conference
Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, today announced that the company's management team will present at the Baird 2014 Health Care Conference on Wednesday, Sept.
Mon Aug 25, 2014
Endocyte Receives Consensus Rating of "Buy" from Brokerages
Shares of Endocyte have been given an average recommendation of "Buy" by the ten ratings firms that are covering the stock, Analyst RN reports .
Fri Aug 22, 2014
Endocyte 72 Hour Deadline Alert: Approximately 72 Hours Remain;...
Investor losses must relate to purchases of the Company's securities during the period between March 21, 2014 and May 2, 2014.
Thu Aug 21, 2014
Endocyte Given Average Recommendation of "Buy" by Analysts
Endocyte has received a consensus rating of "Buy" from the ten ratings firms that are currently covering the stock, American Banking and Market News reports .
Fri Aug 15, 2014
Endocyte, Inc. Scientific Team Selected To Receive 2015 George And...
Endocyte, Inc. , a leader in developing targeted small molecule drug conjugates and companion imaging agents for personalized therapy, today announced that the Company's scientific management team has been selected by the American Chemical Society as the recipient of the 2015 George and Christine Sosnovsky Award for Cancer Research.
Thu Aug 14, 2014
Endocyte Shareholder Alert by Former Louisiana Attorney General: Kahn ...
Kahn Swick & Foti, LLC and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 25, 2014 to file lead plaintiff applications in a securities class action lawsuit against Endocyte, Inc. , if they purchased the Company's securities during the period between March 21, 2014 and May 2, ... (more)
Wed Aug 13, 2014
Shareholder Alert: Levi & Korsinsky, LLP Reminds Investors of Class...
Levi & Korsinsky announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of Indiana on behalf of investors who purchased Endocyte, Inc. common stock between March 21, 2014 and May 2, 2014.
Mon Aug 04, 2014
Endocyte: A Rare Biotech Opportunity With Significant Upside Potential
Endocyte is significantly undervalued considering its various ongoing clinical cancer trials and 85% of its market cap being in cash with zero debt.
Fri Aug 01, 2014
Press release distribution, EDGAR filing, XBRL, regulatory filings
The report is available at 'www.fitchratings.com'. Additional inform... )--Class action securities litigation has been brought on behalf of purchasers of the securities of Endocyte, Inc. between March 21, 2014 and May 2, 201... Diverse Careers, Inc. Announces Orange County Career Fair to Be Held Thursday, August 28, 2014 10:00am to 2:00pm ... (more)
Lieff Cabraser Announces Class Action Litigation Against Endocyte, Inc. - ECYT
If you purchased Endocyte securities during the Class Period, you may move the Court for appointment as lead plaintiff by no later than August 25, 2014.